Principal inclusion criteria GCT3013-03

All Subjects

• Subject must sign an ICF, prior to any screening procedures

• Must be at least 18 years of age

• ECOG performance status score of 0,1 or 2

• Evidence of CD20 positivity at screening

• Has acceptable laboratory parameters

• Subject must have availability of fresh bone marrow material at screening

• A woman with reproductive potential must agree to use adequate contraception during the trial, and for 12 months after the last administration of epcoritamab.

• A woman of childbearing potential must have a negative serum (betahCG) pregnancy test at screening and a negative serum or urine pregnancy test before treatment administration on Day 1 of every cycle.

• A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 12 months after last treatment.

• A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control.

Inclusion Criteria Specific to the R/R CLL Cohort

• Must have active CLL disease that needs treatment

• R/R CLL after receiving at least 2 prior lines of systemic antineoplastic therapy

• Has measurable disease with at least one of the following criteria:

a. ≥5 × 109/L (5,000/μL) B lymphocytes in peripheral blood

b. Presence of measurable lymphadenopathy and/or organomegaly

• Must take prophylaxis for TLS

Inclusion Criteria Specific to the Richter's Syndrome Cohort

• Must have a clinical history of CLL/SLL with biopsy-proven transformation toward aggressive lymphoma (ie, DLBCL subtype).

• Deemed as ineligible for chemoimmunotherapy at investigator's discretion or refuse to receive intensive chemotherapy.

• Must have measurable disease

E.4 Principal exclusion criteria

All Subjects

• Subject received prior treatment with a CD3 × CD20 bispecific antibody.

• Subject received any prior allogeneic HSCT or solid organ transplantation

• Subject received treatment with an anti-cancer agent, eg:

a. Small molecules such as BTK inhibitor, BCL2 inhibitor, or PI3K inhibitor within 5 half-lives prior to the first dose of epcoritamab; or

b. Anti-CD20 mAb or chemotherapy within 2 weeks prior to the first dose of epcoritamab; or

c. Radio-conjugated or toxin conjugated antibody or CAR-T cell therapy within 4 weeks or 5 half-lives, whichever is shorter, prior to the first dose of epcoritamab

d. Subject received treatment with an investigational drug, within 4 weeks or 5 half-lives, whichever is shorter prior to the first dose of epcoritamab.

• Subject has autoimmune disease or other diseases that require permanent or high-dose immunosuppressive therapy.

• Subject has clinically significant cardiac disease

• Subject received vaccination with live vaccines within 28 days prior to the first dose of epcoritamab

• Subject has known central nervous system (CNS) involvement at screening.

• Has had major surgery within 4 weeks prior to enrollment.

• Known medical history or ongoing hepatitis C infection that has not been cured.

• Known history of seropositivity for HIV infection. Note: HIV testing is required at screening only if required per local health authorities or institutional standards.

• Subject is a woman who is pregnant or breast-feeding, or who is planning to become pregnant while enrolled in this trial or within 12 months after the last dose of epcoritamab.

• Subject is a man who plans to father a child while enrolled in this trial or within 12 months after the last dose of epcoritamab.

• Subject has uncontrolled intercurrent illness, such as ongoing or active infection requiring intravenous antibiotics treatment at the time of enrollment or within the

previous 2 weeks prior to the first dose of epcoritamab.

Exclusion Criteria Specific to the R/R CLL Cohort (numbering continues as per Protocol)

• Any history of RS or evidence indicating a potential Richter's transformation.

• Subject is unable to tolerate uric acid reducing medications.

Exclusion Criteria Specific to the Richter's Syndrome Cohort

• Diagnosis of Richter's syndrome not of the DLBCL subtype such as Hodgkin's lymphoma, prolymphocytic leukemia.

• Subject received autologous HSCT within 3 months prior to the first dose of epcoritamab.

• Subject received more than 1 prior line of therapy for RS.